Advances in the Management of Brain Metastases

Advances in the Management of Brain Metastases is organized by Med-IQ and will be held from Oct 11, 2018 - Oct 10, 2019.

Target Audience:
This activity is intended for oncologists and hematologists.

Accreditation/Designation Statements:
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conference Description:
In this 30-minute webcast, expert faculty review recent advances in the management of brain malignancies. In particular, April K.S. Salama, MD, discusses the current understanding of systemic therapy, John Kirkpatrick, MD, PhD, discusses advances in radiation therapy, and Peter Fecci, MD, PhD, discusses surgical improvements for brain metastasis.

Statement of Need:
Estimates show that up to 14% of individuals with cancer in the United States will develop brain metastases. Treating brain metastases remains challenging for oncologists and hematologists; indeed, the survival rate for the majority of patients is less than 1 year. Currently, the mainstay of treatment consists of stereotactic radiosurgery, surgical resection, whole-brain radiation therapy, or a combination of these modalities. Clinicians must be familiar with recent advances in these therapies to provide optimal care for patients with brain metastases.

Learning Objectives:
Upon completion, participants should be able to:
• Understand advances in systemic therapy that can impact the management of brain metastases
• Describe the key differences in rates of recurrence and cognitive decline associated with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases
• Describe the current uses and limitations of laser interstitial thermal therapy for intracranial metastatic disease.